Bispecific antibodies for immune cell retargeting against cancer
Author:
Affiliation:
1. Pfizer BioMedicine Design, Pfizer Inc, San Diego, CA, USA
2. Pfizer BioMedicine Design, Pfizer Inc, Cambridge, MA, USA
3. Pfizer BioMedicine Design, Pfizer Inc, Andover, MA, USA
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2072209
Reference189 articles.
1. Enhancement of Antitumor Immunity by CTLA-4 Blockade
2. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
3. Immune checkpoint inhibitors win the 2018 Nobel Prize
4. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
5. Catumaxomab
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents;European Journal of Immunology;2024-05-28
2. Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry;Bioconjugate Chemistry;2023-11-14
3. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements;Acta Pharmaceutica Sinica B;2023-09
4. A Modular Antibody‐Oligomer T Cell Engager for Applications in Local Therapies;Advanced Therapeutics;2023-07-19
5. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism;Blood;2023-03-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3